Literature DB >> 22742725

A megakaryocyte with no platelets: anti-platelet antibodies, apoptosis, and platelet production.

José Perdomo1, Feng Yan, Beng H Chong.   

Abstract

Primary immune thrombocytopenia (ITP) and drug-induced thrombocytopenia (DITP) are disorders caused primarily by the presence of anti-platelet auto-antibodies (Abs). Hematologists have traditionally seen thrombocytopenia as the result of increased destruction of Ab-coated platelets by the reticuloendothelial system. While accurate, this approach does not fully account for other laboratory observations. There is increasing evidence suggesting a significant cellular component in the etiology of both ITP and DITP. In ITP, megakaryocytes (Mks) show characteristics consistent with increased apoptosis, which correlates with a reduction in platelet production capacity. Platelet production by Mks is impaired in both the bone marrow of ITP patients and in Mks produced in vitro when treated with ITP or DITP auto-Abs. Recently, it was shown that anti GPIb/IX DITP Abs act directly on Mks and induce apoptosis, hinder differentiation, and prevent platelet production. The origin of pathological megakaryocytic apoptosis is yet to be explored in more detail but current observations imply that there is a direct contribution by anti-platelet Abs. Here we review the evidence for Ab-mediated megakaryocytic damage in ITP and DITP, examine possible molecular mechanisms and consider potential clinical implications.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22742725     DOI: 10.3109/09537104.2012.669508

Source DB:  PubMed          Journal:  Platelets        ISSN: 0953-7104            Impact factor:   3.862


  8 in total

1.  Comparative study of IgG binding to megakaryocytes in immune and myelodysplastic thrombocytopenic patients.

Authors:  Doaa I Elzaeem; Esmat A El Sharkawi; Eman M Zaki; Ayman G Ghobrial; Aliaa S Abd El-Fatah; Waleed M Abd El-Hamed
Journal:  Ann Hematol       Date:  2021-05-13       Impact factor: 3.673

2.  Immune thrombocytopenia: antiplatelet autoantibodies inhibit proplatelet formation by megakaryocytes and impair platelet production in vitro.

Authors:  Muna Iraqi; Jose Perdomo; Feng Yan; Philip Y-I Choi; Beng H Chong
Journal:  Haematologica       Date:  2015-02-14       Impact factor: 9.941

3.  Antibody binding to megakaryocytes in vivo in patients with immune thrombocytopenia.

Authors:  Donald M Arnold; Ishac Nazi; Lisa J Toltl; Catherine Ross; Nikola Ivetic; James W Smith; Yang Liu; John G Kelton
Journal:  Eur J Haematol       Date:  2015-03-13       Impact factor: 2.997

4.  2-O, 3-O desulfated heparin mitigates murine chemotherapy- and radiation-induced thrombocytopenia.

Authors:  Elizabeth Tkaczynski; Abinaya Arulselvan; John Tkaczynski; Stephen Avery; Liqing Xiao; Beverly Torok-Storb; Kraig Abrams; Narayanam V Rao; Gregory Johnson; Thomas P Kennedy; Mortimer Poncz; Michele P Lambert
Journal:  Blood Adv       Date:  2018-04-10

5.  Helicobacter pylori Regulates the Apoptosis of Human Megakaryocyte Cells via NF-κB/IL-17 Signaling.

Authors:  Huyi Lei; Yongyong Ma; Jie Tan; Qifa Liu
Journal:  Onco Targets Ther       Date:  2021-03-19       Impact factor: 4.147

Review 6.  Pathophysiology and management of primary immune thrombocytopenia.

Authors:  Hirokazu Kashiwagi; Yoshiaki Tomiyama
Journal:  Int J Hematol       Date:  2013-05-24       Impact factor: 2.490

7.  Inhibition of Tropomyosin Receptor Kinase A Signaling Negatively Regulates Megakaryopoiesis and induces Thrombopoiesis.

Authors:  Ayse Kizilyer; Meera V Singh; Vir B Singh; Sumanun Suwunnakorn; James Palis; Sanjay B Maggirwar
Journal:  Sci Rep       Date:  2019-02-26       Impact factor: 4.379

Review 8.  Role of romiplostim in splenectomized and nonsplenectomized patients with immune thrombocytopenia.

Authors:  Jose Perdomo
Journal:  Immunotargets Ther       Date:  2016-02-22
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.